FSD Pharma Inc
CNSX:HUGE
Income Statement
Earnings Waterfall
FSD Pharma Inc
Income Statement
FSD Pharma Inc
| Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
+20%
|
0
-21%
|
0
-26%
|
0
-61%
|
0
-71%
|
0
+3 275%
|
0
-12%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Gross Profit | |||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(1)
N/A
|
(1)
+41%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
(14)
|
(17)
|
(25)
|
(33)
|
(30)
|
(38)
|
(25)
|
(35)
|
(33)
|
(35)
|
(30)
|
(58)
|
(65)
|
(57)
|
(34)
|
(30)
|
(25)
|
(27)
|
(27)
|
(31)
|
(28)
|
(24)
|
(19)
|
(12)
|
|
| Selling, General & Administrative |
(13)
|
(16)
|
(19)
|
(26)
|
(22)
|
(29)
|
(23)
|
(31)
|
(25)
|
(24)
|
(18)
|
(36)
|
(41)
|
(37)
|
(23)
|
(20)
|
(17)
|
(17)
|
(16)
|
(18)
|
(15)
|
(14)
|
(13)
|
(9)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(6)
|
(8)
|
(7)
|
(9)
|
0
|
(6)
|
(5)
|
(3)
|
(5)
|
(7)
|
(8)
|
(8)
|
0
|
0
|
(2)
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(4)
|
(5)
|
(4)
|
(4)
|
(7)
|
(7)
|
(7)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(4)
|
(3)
|
(1)
|
|
| Other Operating Expenses |
0
|
0
|
(6)
|
(7)
|
(7)
|
(7)
|
0
|
0
|
0
|
0
|
0
|
(8)
|
(8)
|
(13)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(4)
|
0
|
|
| Operating Income |
(13)
N/A
|
(16)
-22%
|
(25)
-49%
|
(33)
-36%
|
(30)
+10%
|
(38)
-27%
|
(26)
+31%
|
(36)
-37%
|
(33)
+9%
|
(35)
-6%
|
(30)
+14%
|
(58)
-93%
|
(65)
-14%
|
(57)
+12%
|
(34)
+41%
|
(30)
+12%
|
(25)
+16%
|
(27)
-9%
|
(27)
-2%
|
(31)
-14%
|
(28)
+9%
|
(24)
+14%
|
(19)
+21%
|
(12)
+37%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
8
|
14
|
8
|
11
|
(2)
|
(13)
|
(11)
|
(19)
|
(11)
|
(7)
|
2
|
4
|
3
|
2
|
(0)
|
(0)
|
(0)
|
0
|
1
|
0
|
4
|
6
|
6
|
6
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(4)
|
(4)
|
(5)
|
(4)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(6)
N/A
|
(2)
+68%
|
(17)
-838%
|
(22)
-29%
|
(32)
-47%
|
(51)
-57%
|
(38)
+25%
|
(55)
-44%
|
(45)
+19%
|
(43)
+4%
|
(28)
+34%
|
(55)
-93%
|
(64)
-16%
|
(56)
+12%
|
(34)
+40%
|
(30)
+12%
|
(25)
+16%
|
(27)
-6%
|
(27)
+0%
|
(31)
-17%
|
(29)
+8%
|
(23)
+21%
|
(18)
+20%
|
(10)
+43%
|
|
| Net Income | |||||||||||||||||||||||||
| Income from Continuing Operations |
(6)
|
(2)
|
(17)
|
(22)
|
(32)
|
(51)
|
(38)
|
(55)
|
(45)
|
(43)
|
(28)
|
(55)
|
(64)
|
(56)
|
(34)
|
(30)
|
(25)
|
(27)
|
(27)
|
(31)
|
(29)
|
(23)
|
(18)
|
(10)
|
|
| Net Income (Common) |
(6)
N/A
|
(2)
+68%
|
(17)
-838%
|
(23)
-36%
|
(35)
-51%
|
(56)
-59%
|
(38)
+32%
|
(60)
-58%
|
(49)
+19%
|
(46)
+5%
|
(32)
+31%
|
(61)
-90%
|
(69)
-14%
|
(61)
+12%
|
(35)
+42%
|
(31)
+11%
|
(22)
+28%
|
(24)
-6%
|
(24)
+1%
|
(28)
-17%
|
(29)
-4%
|
(23)
+21%
|
(18)
+20%
|
(10)
+43%
|
|
| EPS (Diluted) |
-1.05
N/A
|
-0.27
+74%
|
-2.88
-967%
|
-3.37
-17%
|
-4.99
-48%
|
-7.38
-48%
|
-5.4
+27%
|
-7.38
-37%
|
-5.41
+27%
|
-3.65
+33%
|
-2.64
+28%
|
-2.25
+15%
|
-1.92
+15%
|
-1.67
+13%
|
-1
+40%
|
-0.8
+20%
|
-0.58
+28%
|
-0.62
-7%
|
-0.61
+2%
|
-0.7
-15%
|
-0.74
-6%
|
-0.59
+20%
|
-0.47
+20%
|
-0.26
+45%
|
|